Abstract:Objective To observe the efficacy and safety of rifabutin and furazolidone included triple regimen and minocycline plus furazolidone included quadruple regimen in eradicating refractory H.pylori infection.Methods A total of 146 patients who failed (≥ two times) to treat H.pylori with standard antiH.pylori therapy were selected and divided into esomeprazole,rifabutin and furazolidone treatment group (ERF group,n =74) and esomeprazole,minocycline,furazolidone and bismuth potassium citrate group (EMFB group,n =72).The duration of treatment were both 10 days.Liver and renal functions were examined within three days after therapy.13C or 14 C-urease breath test was performed one month after the medication withdrawal.The patients were followed up once every two weeks during the treatment period.The medication and adverse reactions were recorded in detail.The compliance and rates of adverse events in two groups were compared and analyzed.The eradication rates of the two groups and subgroups were compared by intention-to-treat (ITT) and per-protocol (PP) analyses.The cost-effectiveness of the two groups was evaluated with cost effectiveness analysis (CEA).The cost/effectiveness (C/E) ratio was calculated by PP.Chi-square test and t test were used for statistical analysis.Results There was no significant difference in complicance between ERF group and EMFB group (90.5％ vs.90.3％,P ＞0.05).There was no significant difference in H.pylori eradication rate between ERF group and EMFB group analyzed by ITT (82.4％ vs.84.7％,P ＞0.05).Analyzed by PP,there were no significant differences in H.pylori eradication rate between ERF group and EMFB group (91.0％ vs.93.8％),between male subgroup and female subgroup of ERF group (87.9％ vs.94.1％),between subgroup with age less than 60 years and subgroup with age over 60 years of ERF group (89.7％ vs.92.9％),between male subgroup and female subgroup of EMFB group (89.7％ vs.97.2％) and between subgroup with age less than 60 years and subgroup with age over 60 years of EMFB group (93.6％ vs.94.4％) (all P ＞ 0.05).There were no statistically significant differences in the rate of adverse events between ERF group and EMFB group (20.3％ vs.22.2％),between male subgroup and female subgroup of ERF group (25.0％ vs.15.8％),between subgroup with age less than 60 years and subgroup with age over 60 years of ERF group (26.2％ vs.12.5％),between male subgroup and female subgroup of EMFB group (19.4％ vs.24.4％) and between subgroup with age less than 60 years and subgroup with age over 60 years of EMFB group (24.5％ vs.15.8％)(all P ＞ 0.05).Fixed daily cost,total cost and C/E of ERF group was RMB 59.0 yuan,RMB 590.5 yuan and 648.9,respectively;and the eradication rate was 91.0％ (61/67).Fixed daily cost,total cost and C/E of EMFB group was RMB 32.9 yuan,RMB 329.1 yuan and 350.9,respectively;and the eradication rate was 93.8％ (61/65).Conclusions Rifabutin and furazolidone included triple regimen and minocycline plus furazolidone included quadruple regimen both have good efficacy,safety and compliance in the eradication of refractory H.pylori infection,and the latter is better.

Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Single-Arm, Prospective, Interventional Study of Helicobacter pylori Eradication Rescue Therapy with Rifabutin, Metronidazole, and Vonoprazan

Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties

Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies

Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.

Efficacy and Safety of Rifabutin and Furazolidone Included Triple Regimen and Minocycline Plus Furazolidone Included Quadruple Regimen in Eradicating Refractory Helicobacter Pylori Infection

Rifabutin for the Treatment of Helicobacter pylori Infection: A Review

Newer Therapies for Refractory Helicobacter pylori Infection in Adults: A Systematic Review

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

Effectiveness of Rifabutin-Based Regimens in Treating Helicobacter pylori Infections

Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States

Outcomes of Furazolidone- and Amoxicillin-Based Quadruple Therapy for Helicobacter Pylori Infection and Predictors of Failed Eradication.

Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori

Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy

Seven‐Day Vonoprazan‐Based Triple Therapy as First‐Line Helicobacter pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection

Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study

Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy.

Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of <i>Helicobacter pylori</i> infection previously failed in eradication: A real-world, retrospective clinical study in China